Canada markets closed

CPRX Jun 2024 22.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.35000.0000 (0.00%)
At close: 09:43AM EDT
Full screen
Previous Close0.3500
Open0.0700
Bid0.0000
Ask0.1000
Strike22.50
Expire Date2024-06-21
Day's Range0.0700 - 0.3500
Contract RangeN/A
Volume10
Open Interest210
  • GlobeNewswire

    Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

    CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE® (amifampr

  • GlobeNewswire

    Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

    CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming Jefferies Global Healthcare Conferen

  • GlobeNewswire

    Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

    Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of $66.8 Million, a 16.2% YoY Increase Robust Revenue Momentum for FIRDAPSE® Successfully Commenced the U.S. Launch of AGAMREE® on March 13, 2024 Reported AGAMREE® Q1 2024 Net Product Revenues of $1.2 Million for the First Two Weeks of Commercial Availability Early AGAMREE® Launch Indicators Highlight Prom